Pharmaron Beijing Co (SZSE:300759) Cash And Cash Equivalents : ¥4,633 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Cash And Cash Equivalents?

Pharmaron Beijing Co's quarterly cash and cash equivalents increased from Sep. 2023 (¥2,058.72 Mil) to Dec. 2023 (¥5,918.92 Mil) but then stayed the same from Dec. 2023 (¥5,918.92 Mil) to Mar. 2024 (¥4,633.34 Mil).

Pharmaron Beijing Co's annual cash and cash equivalents declined from Dec. 2021 (¥3,543.82 Mil) to Dec. 2022 (¥1,497.48 Mil) but then increased from Dec. 2022 (¥1,497.48 Mil) to Dec. 2023 (¥5,918.92 Mil).

Pharmaron Beijing Co Cash And Cash Equivalents Historical Data

The historical data trend for Pharmaron Beijing Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Cash And Cash Equivalents Chart

Pharmaron Beijing Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

4,459.85

2,942.35

3,543.82

1,497.48

5,918.92

Pharmaron Beijing Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															2,055.50	2,512.73	2,058.72	5,918.92	4,633.34

Pharmaron Beijing Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Pharmaron Beijing Co (SZSE:300759) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Pharmaron Beijing Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co (SZSE:300759) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

03759:Hong Kong 17Q1:Germany

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.

Executives

Lou Xiao Qiang	Directors, executives
Zheng Bei	Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines